Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in pediatric primary IgA nephropathy
2024-520167-13-00Phase 3Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in IgA nephropathy (IgAN) and IgA vasculitis nephritis, sponsored by Alexion Pharmaceuticals. Primary endpoint: Change from baseline in proteinuria based on UPCR at Week 34. Planned start Jun 2025; status: authorised.
02
Drugs
ravulizumab
03
Conditions
IgA nephropathy (IgAN)IgA vasculitis nephritis
Beyond the preview
Go deeper on 2024-520167-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520167-13-00.